Emerging Targets in Clear Cell Renal Cell Carcinoma

SIMPLE SUMMARY: Immuno-Oncology (IO) based combinations are now the standard of care for frontline advanced clear cell renal cell carcinoma. Despite the unprecedented durable efficacy of such combinations, many patients do not respond to IO or will eventually develop resistance. This review summariz...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Yu-Wei, Rini, Brian I., Beckermann, Kathryn E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561986/
https://www.ncbi.nlm.nih.gov/pubmed/36230766
http://dx.doi.org/10.3390/cancers14194843

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9561986/
https://www.ncbi.nlm.nih.gov/pubmed/36230766
http://dx.doi.org/10.3390/cancers14194843

Ejemplares similares